Lyell Immunopharma Chair Dr. Richard Klausner takes medical leave; Friedman named interim Chair

Lyell Immunopharma, Inc.

Dr. Richard Klausner takes temporary medical leave; expected return early 2022. Resigns as Executive Chairman effective Oct 1, 2022 but remains Chair.
Cathy Friedman, lead independent director, appointed interim Chair of Board during Klausner's absence.
Company states leave will not impact IND timelines (four submissions by end 2022) or corporate objectives.
Klausner issued a letter expressing confidence in management and team to continue mission during his leave.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Dr. Richard Klausner

Chair of the Board

LYEL · Lyell Immunopharma, Inc.

Effective: 2022-10-01
Successor: Cathy Friedman
Filed: September 30, 2021, 7:59 PM ET

On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022.

Appointed (interim)

Cathy Friedman

interim Chair of the Board

LYEL · Lyell Immunopharma, Inc.

Effective: 2021-09-29
Filed: September 30, 2021, 7:59 PM ET

The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Richard Klausner resigned as Chair of the Board at Lyell Immunopharma, Inc..

Action: resigned
Role: Chair of the Board

Exact text from the filing

On September 29, 2021, Dr. Richard Klausner, the Chair of the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) informed the Company that (a) he will take a temporary medical leave of absence and is expected to return in early 2022 (the “Leave”) and (b) he will also be resigning from his position as Executive Chairman of the Company and will no longer be an employee, effective October 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Cathy Friedman was elected as interim Chair of the Board at Lyell Immunopharma, Inc..

Action: elected
Role: interim Chair of the Board

Exact text from the filing

The Board has elected Cathy Friedman, its lead independent director, to serve as the interim Chair of the Board during Dr. Klausner’s absence.

View on SEC.gov

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-287960

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.